SARS-CoV-2 causing the worldwide pandemic has changed people's life in multiple aspects
dramatically since it's first identified in Wuhan, China at the end of 2019. While the numbers …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Neutralizing antibodies can block infection, clear pathogens, and are essential to provide
long-term immunity. Since the onset of the pandemic, SARS-CoV-2 neutralizing antibodies …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2
on host cells is essential for viral entry. RBD is the dominant target for neutralizing …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and …